CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Carl Hansen

Chairman, CEO and President, AbCellera Biologics Inc.

Search every verified Carl Hansen interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Carl Hansen, chairman, CEO, and president of AbCellera Biologics, discussed the company’s pipeline and partnerships during its Q2 2026 earnings call. He noted two new T-cell engager collaborations with Vertex and Jazz, which he said added over $110 million in upfront cash, with potential for downstream payments and tiered royalties. He also highlighted the upcoming topline results for ABCL 635, a treatment for moderate to severe hot flashes associated with menopause, describing interim phase 1 data as showing robust and sustained target engagement and saying enrollment in a phase 2 study had accelerated and completed initial dosing. In earlier appearances, Hansen spoke about the broader challenges and opportunities in biotech. He described drug development as a long, risky, and expensive process, citing an average 10-year timeline and a 5% success rate, and argued that the industry as a whole makes a negative return on investment. He also reflected on AbCellera’s role in developing a COVID-19 antibody therapy with Eli Lilly, stating that the treatment received emergency use authorization in the U.S. and Canada and had helped over 600,000 people in the U.S. He expressed pride in the company’s pandemic response and criticized provincial decisions in Canada that he said left the therapy unused despite regulatory approval.

Recent appearances

  • AbCellera Biologics Q2 2026 Earnings Call | Internal Drug Pipeline Programs Scale

    August 06, 2026 · 📺 i101

    AbCellera Biologics Q2 2026 Earnings Conference Call. Twitter - https://x.com/i101yt If you find our work useful, please support us by purchasing a Super Thanks— it truly helps us a lot. #earningscall #StockMarketNews #conferenceCall Earnings Call | Earnings Conference Call | Earnings concall | concall | quarterly results | Stock News | Full Year results | Fiscal Year results | investment news | stock latest news | Annual Meeting of Shareholders | Annual Meeting of Unitholders | Special and Annual Meeting of Shareholders | AGM | Annual General Meeting If you want us to remove your compan…

    Watch on YouTube ↗

  • Why medicines are miracles of science and technology | AbCellera CEO Carl Hansen

    March 12, 2025 · 📺 University of Austin (UATX)

    Biotech is at a watershed moment - the pace of scientific discovery is accelerating rapidly, but developing new drugs remains an immensely difficult and risky endeavor. Carl Hansen, CEO of AbCellera, reveals the hidden challenges, game-changing innovations, and his own journey at the cutting edge of biotech. Don't miss the insights and live Q&A. 00:00:00 Carl Hansen's brief intro 00:00:23 Carl Hansen's Speech 00:47:57 Q&A

    Watch on YouTube ↗

  • Prediction is very difficult, especially if it’s about the future

    July 30, 2024 · 📺 pharmaphorum media limited

    In a new episode of the pharmaphorum podcast, host Nicole Raleigh welcomes Carl Hansen, CEO of AbCellera, for a conversation on the discovery and acceleration of antibody therapeutics.

    Watch on YouTube ↗

  • Decentralizing biotech | MaRS Impact Health 2022

    July 15, 2022 · 📺 MaRS Discovery District

    ABOUT THE SESSION The speedy creation of COVID vaccines showed the potential of collaboration and flexible models for biotech development. Centralized funding and top-down decision-making are giving way to a more decentralized network where startups run by scientist-CEOs are creating innovative partnerships with pharmaceutical companies. How is this model working in practice? And will it lead to better therapies faster? Speakers: Karolina Valente - VoxCell BioInnovation Brendan Frey - Deep Genomics Carl Hansen - AbCellera Hosted by: Carly Weeks - The Globe and Mail ABOUT MaRS DISCOVERY DIST…

    Watch on YouTube ↗

  • Company of the Year – Anchor – AbCellera | 2021 Technology Impact Awards

    November 19, 2021 · 📺 BC Tech

    Carl Hansen, CEO, AbCellera, accepts the #2021TIAs Company of the Year – Anchor award for AbCellera.

    Watch on YouTube ↗

  • 2021 Bloom Burton Award Winner - Carl Hansen of AbCellera Biologics

    October 19, 2021 · 📺 Bloom Burton & Co.

    Carl Hansen is a recipient of the 2021 Bloom Burton Award. The Bloom Burton Award honours an individual scientist, inventor, executive, entrepreneur, industry leader, or policy maker who made the greatest contribution to Canada’s innovative healthcare industry in the previous year. Nominees are accepted from any of the biotechnology, pharmaceutical, medical device, diagnostic/imaging, research instrumentation, consumer health, services or healthcare IT sectors, and equal consideration is given to contributions across any stage of development – from discovery to commercial end markets. The B…

    Watch on YouTube ↗

  • Overnight Billionaire Reveals Management Style That Has Allowed Him To Scale

    October 12, 2021 · 📺 Forbes

    At the #Under30Summit, AbCellera CEO Carl Hansen tells Alex Knapp: "What is important is that you have great people around you and you let go and let them do enough things by themselves and trust them." #ForbesUnder30 Subscribe to FORBES: https://www.youtube.com/user/Forbes?s... Stay Connected Forbes newsletters: https://newsletters.editorial.forbes.com Forbes on Facebook: http://fb.com/forbes Forbes Video on Twitter:   / forbes   Forbes Video on Instagram:   / forbes   More From Forbes: http://forbes.com Forbes covers the intersection of entrepreneurship, wealth, technology, business and…

    Watch on YouTube ↗

  • Billionaire Antibody Innovator Asked: What Does The World Looks Like Post-COVID-19?

    October 12, 2021 · 📺 Forbes

    At the #Under30Summit, Alex Knapp asks AbCellera CEO Carl Hansen what the world looks like post-COVID-19. #ForbesUnder30 Read the full story on Forbes: Subscribe to FORBES: https://www.youtube.com/user/Forbes?s... Stay Connected Forbes newsletters: https://newsletters.editorial.forbes.com Forbes on Facebook: http://fb.com/forbes Forbes Video on Twitter:   / forbes   Forbes Video on Instagram:   / forbes   More From Forbes: http://forbes.com Forbes covers the intersection of entrepreneurship, wealth, technology, business and lifestyle with a focus on people and success.

    Watch on YouTube ↗

  • How CEO Created First Authorized Antibody Treatment For COVID-19 -- And Became Overnight Billionaire

    October 12, 2021 · 📺 Forbes

    At the #Under30Summit, AbCellera CEO Carl Hansen told Alex Knapp how he created the first authorized antibody treatment for COVID-19 and became an overnight billionaire. #ForbesUnder30 Read the full story on Forbes: Subscribe to FORBES: https://www.youtube.com/user/Forbes?s... Stay Connected Forbes newsletters: https://newsletters.editorial.forbes.com Forbes on Facebook: http://fb.com/forbes Forbes Video on Twitter:   / forbes   Forbes Video on Instagram:   / forbes   More From Forbes: http://forbes.com Forbes covers the intersection of entrepreneurship, wealth, technology, business an…

    Watch on YouTube ↗

  • AbCellera

    April 20, 2021 · 📺 Brian Crombie

    AbCellera. All my podcasts and videos can be accessed any time on my web site https://briancrombie.com which holds repository of all my shows. I'm adding new sessions 5 times a week. The Brian Crombie Radio Hour is every night, Monday to Friday on line at SAUGA 960 am at 7:00 pm. Please subscribe to my YouTube channel. Stream, listen, watch and share. Thank You!

    Watch on YouTube ↗

  • AbCellera CEO on effectiveness of Covid-19 anitbody treatment

    January 13, 2021 · 📺 CNBC Television

    AbCellera Biologics CEO Carl Hansen joins 'Closing Bell' to discuss the company's partnership with Eli Lilly in developing monoclonal antibody treatment and the company's Covid-19 treatments. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC » Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in busin…

    Watch on YouTube ↗

  • Founder Stories: Carl Hansen - Co-Founder and CEO of AbCellera, next-generation antibody discovery

    June 05, 2020 · 📺 Axial

    AbCellera is an emerging antibody discovery company led by Carl Hansen, a professor at the University of British Columbia. Formed around his core inventions on microfluidic valves, AbCellera combines microfluidics and next-generation sequencing to identify new antibodies. Similar to Adimab, AbCellera is of interest due to the unique economics it generates. Instead of developing a drug internally, the business model discovers unique molecular matter and licenses it out to companies whose core competency is clinical development. With the high clinical demand and vast target space for antibodies…

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →